Abstract
Guidelines for chronic obstructive pulmonary disease (COPD) management are based largely on results from double-blind randomised controlled trials (RCTs) of efficacy. These trials have high internal validity and test whether a drug is efficacious, but they are conducted in highly selected populations that may differ significantly from patients with COPD seen in routine practice.We compared the baseline characteristics, healthcare use and outcomes between the Salford Lung Study (SLS), an open-label effectiveness RCT, with six recent large-scale efficacy RCTs. We also calculated the proportion of SLS patients who would have been eligible for inclusion in an efficacy RCT by applying the inclusion criteria used in efficacy trials of combination treatments.SLS patients were older, included more females and more current smokers, had more comorbidities (including asthma), and had more often experienced exacerbations prior to inclusion. In the SLS, rates of moderate or severe exacerbations, incidence of overall serious adverse events (SAEs), and SAEs of pneumonia were more frequent. A maximum of 30% of patients enrolled in the SLS would have been eligible for a phase IIIa regulatory exacerbation study.Patients in large COPD efficacy RC...Continue Reading
References
Jan 28, 2005·Respiratory Medicine·Kjetil HerlandLeif Bjermer
Nov 23, 2006·Respiratory Medicine·Justin TraversRichard Beasley
Jun 6, 2009·Trials·Shaun Treweek, Merrick Zwarenstein
Aug 14, 2010·Respiratory Medicine·Fernie Penning-van BeestRon Herings
Aug 13, 2011·BMC Pulmonary Medicine·Paul W JonesWen-Hung Chen
Oct 29, 2011·Respiratory Medicine·Amir SharafkhanehUbaldo J Martin
Jun 8, 2013·Thorax·Steven WalkerRichard Beasley
Nov 28, 2013·Respiration; International Review of Thoracic Diseases·Nicola ScichiloneVincenzo Bellia
Jan 5, 2014·Clinical and Translational Gastroenterology·Amit G SingalAkbar K Waljee
Jan 17, 2014·The Lancet. Respiratory Medicine·Jadwiga A WedzichaDonald Banerji
Jan 17, 2014·The Lancet. Respiratory Medicine·Mark T DransfieldPeter M A Calverley
Feb 25, 2014·Annals of the American Thoracic Society·Gary W K WongJerry Krishnan
Mar 7, 2014·PloS One·Annemarije L KruisNiels H Chavannes
Mar 8, 2014·Thorax·John P NewAshley Woodcock
Jun 24, 2014·Respiratory Medicine·J A WedzichaUNKNOWN FORWARD Investigators
Apr 17, 2015·BMC Medical Informatics and Decision Making·Hanaa F ElkheniniNawar Diar Bakerly
Sep 5, 2015·Respiratory Research·Nawar Diar BakerlyJørgen Vestbo
Nov 4, 2015·Respiratory Medicine·Keele E WurstNeil Barnes
Apr 20, 2016·PloS One·Jason FooYogesh Punekar
May 18, 2016·The New England Journal of Medicine·Jadwiga A WedzichaUNKNOWN FLAME Investigators
Aug 16, 2016·The New England Journal of Medicine·Ian Ford, John Norrie
Sep 7, 2016·The New England Journal of Medicine·Jørgen VestboUNKNOWN Salford Lung Study Investigators
Sep 25, 2016·Respiratory Research·David M G HalpinDavid B Price
Apr 8, 2017·Lancet·Jørgen VestboDave Singh
Jul 7, 2017·The European Respiratory Journal·Roberto Rodriguez-RoisinUNKNOWN all previous and current members of the Science Committee and the Board of Directors of GOLD (goldcopd.org/committees/)
Citations
Sep 8, 2018·The European Respiratory Journal·Alvar AgustiAlberto Papi
Feb 23, 2018·The European Respiratory Journal·Gerard J Criner
Jan 14, 2020·Advances in Therapy·David A LeatherMike Thomas
Dec 6, 2019·Respiratory Research·Hannah R WhittakerJennifer K Quint
Mar 28, 2020·American Journal of Respiratory and Critical Care Medicine·Jørgen Vestbo
Aug 20, 2019·Respiratory Research·Stefan AndreasTim Friede
May 15, 2019·Respirology : Official Journal of the Asian Pacific Society of Respirology·Steven McKinstryJames Fingleton
Feb 7, 2020·Pulmonary Therapy·Mario CazzolaMaria Gabriella Matera
Sep 19, 2020·Trials·Kim GemzoeElaine Irving
May 19, 2020·ERJ Open Research·Cristina CalarasuStefan Frent
Jul 4, 2020·The European Respiratory Journal·Alexander G MathioudakisUNKNOWN DECODE-NET (DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork) Investigators
Oct 22, 2020·ERJ Open Research·Jørgen VestboDavid Price
Mar 31, 2021·Therapeutic Advances in Respiratory Disease·Nawar Diar BakerlyJohn P New
Jun 5, 2021·ERJ Open Research·Catherine HarveyJoanne Fletcher